ADPT vs ZYME

ADPT's Advanced Deterministic Scorecard reveals severe financial health concerns: a Piotroski F-Score of 1/9 indicates extreme weakness, with no positive signals in profitability, cash flow, or leverage management. The Altman Z-Score is unavailable, but the company's negative ROE (-27.82%), negative operating margin (-17.82%), and high debt/equity (0.93) suggest significant distress risk. Despite strong revenue growth (51% YoY) and a history of earnings surprises, the stock trades at a forward P/E of -48.78, reflecting deep losses and speculative valuation. Insider selling totaling $12.73M in six months further undermines confidence, signaling potential internal skepticism about near-term prospects.

ZYME exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9, indicating a failing financial trajectory. Despite a strong liquidity position (Current Ratio 5.88) and low debt, the company has suffered a catastrophic revenue collapse of -91.90% YoY. There is a stark divergence between the 'Strong Buy' analyst consensus and the bearish insider activity, with executives selling $4.67M in shares. The valuation is speculative, trading at a high Price/Sales multiple of 19.23 despite negative margins and shrinking top-line growth.